Literature DB >> 31579210

The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer.

Norihito Soga1, Yuji Ogura1, Toshiaki Wakita2, Takumi Kageyama3, Jun Furusawa1.   

Abstract

OBJECTIVES: We used a new GP score (Gleason score multiplied by prostate-specific antigen) without the T stage as a predictive value for biochemical failure (BCF) after prostatectomy.
MATERIALS AND METHODS: We assessed 459 prostate cancer patients who underwent prostatectomies at our institution. Three sub-groups were defined in terms of D'Amico classification risk (low, intermediate, and high) and Gleason score (low, < 50; intermediate, 50-100; and high GP score, > 100). Risk factors for BCF were evaluated by multivariate analysis with a Cox hazard model. A log-rank test was used to compare the BCF rate in the 2 groups.
RESULTS: There was nosignificant difference in the non-BCF rate between the lowrisk and low GP score subgroups or the intermediate risk andintermediate GP score subgroups. In contrast, the non-BCFrate of the high GP score subgroup (42.1%) was significantlylower than that of the high-risk subgroup (66.1%, log-rankp = 0.008). Based on multivariate analysis, a high GP score(p = 0.001; HR 3.78; 95%CI 1.95-7.35) was a significant independent risk factor for BCF after prostatectomy.
CONCLUSION: The GP score, consisting of two absolute numbers, may be a valuable predictive factor for BCF after prostatectomy, especially in the high-risk failure group.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Gleason score; Predictive factors; Prostate cancer; Prostate-specific antigen

Year:  2019        PMID: 31579210      PMCID: PMC6771044          DOI: 10.1159/000499298

Source DB:  PubMed          Journal:  Curr Urol        ISSN: 1661-7649


  20 in total

1.  Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer.

Authors:  P Sooriakumaran; D P Lovell; A Henderson; P Denham; S E M Langley; R W Laing
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-12       Impact factor: 4.126

2.  Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancer.

Authors:  Yasuo Yoshioka; Takehiro Inoue
Journal:  Strahlenther Onkol       Date:  2007-09       Impact factor: 3.621

3.  Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.

Authors:  Adam C Reese; Matthew R Cooperberg; Peter R Carroll
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

4.  Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy.

Authors:  Ken Yoshida; Hideya Yamazaki; Satoaki Nakamura; Koji Masui; Tadayuki Kotsuma; Hironori Akiyama; Eiichi Tanaka; Yasuo Yoshioka
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

5.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  Validation of the Prostate Cancer Risk Index (PRIX): a simple scoring system to predict risk of biochemical relapse after radical prostatectomy for prostate cancer.

Authors:  Takahiro Yoshida; Masashi Nakayama; Kyosuke Matsuzaki; Yasuyuki Kobayashi; Ken Takeda; Yasuyuki Arai; Ken-Ichi Kakimoto; Kazuo Nishimura
Journal:  Jpn J Clin Oncol       Date:  2011-10-04       Impact factor: 3.019

7.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.

Authors:  Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

8.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.

Authors:  Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

9.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

10.  Clinical predictors and recommendations for staging computed tomography scan among men with prostate cancer.

Authors:  Rachel Risko; Selin Merdan; Paul R Womble; Christine Barnett; Zaojun Ye; Susan M Linsell; James E Montie; David C Miller; Brian T Denton
Journal:  Urology       Date:  2014-10-05       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.